RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. [electronic resource]
Producer: 20160209Description: 6377 p. digitalISSN:- 2041-1723
- Adenocarcinoma -- drug therapy
- Adenocarcinoma of Lung
- Afatinib
- Aniline Compounds -- pharmacology
- Antineoplastic Agents -- pharmacology
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- Cell Line, Tumor
- Disease Progression
- Drug Resistance, Neoplasm -- drug effects
- ErbB Receptors -- antagonists & inhibitors
- Erlotinib Hydrochloride -- pharmacology
- Gefitinib
- Gene Expression Regulation, Neoplastic
- Humans
- Lung -- drug effects
- Lung Neoplasms -- drug therapy
- Mutation
- Protein Kinase Inhibitors -- pharmacology
- Proto-Oncogene Proteins c-bcl-2 -- genetics
- Quinazolines -- pharmacology
- Recurrence
- Retinoblastoma Protein -- deficiency
- Signal Transduction
- Small Cell Lung Carcinoma -- drug therapy
- Sulfonamides -- pharmacology
- bcl-X Protein -- genetics
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
There are no comments on this title.
Log in to your account to post a comment.